What does ACRO Biomedical Co., Ltd. do?

ACRO Biomedical Co., Ltd. (6748.TWO) operates in the Medical - Specialties industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6748.TWO's market cap?

ACRO Biomedical Co., Ltd. (6748.TWO) has a market capitalization of approximately $13.00 billion, as of August 27, 2026, based on the most recent share price and shares outstanding.

Does 6748.TWO pay a dividend?

No — ACRO Biomedical Co., Ltd. (6748.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6748.TWO profitable?

ACRO Biomedical Co., Ltd. (6748.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6748.TWO

ACRO Biomedical Co., Ltd.

TWO·Medical, Specialties · Healthcare

NT$182.50NT$7.00−3.69%

Market capNT$13.00B·Market closed·Aug 27 5:19 AM UTC

Price Chart

NT$182.50−NT$7.00 (−3.69%)today

+555.30%CAGR +45.65%

Select date range

FromTo

Jul 27, 2021Aug 27, 2021 → Aug 27, 2026· 5.0 yrsAug 27, 2026

Key Metrics

6748.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$79.14M

Net Income−NT$118.19M

Net Margin−149.3%

Operating Cash Flow−NT$108.49M

Capital ExpendituresNT$13.83M

Free Cash Flow−NT$122.32M

Return on Equity−11.1%

Return on Invested Capital−4.3%

Net CashNT$883.05M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6748.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6748.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6748.TWO and 80,000+ other tickers.

About ACRO Biomedical Co., Ltd.

ACRO Biomedical Co., Ltd. is dedicated to the creation and manufacturing of biomaterial-based medical devices, specifically designed for applications in human tissue engineering and regenerative medicine. This company was established on June 26, 2014, and operates primarily from its headquarters in Kaohsiung, Taiwan.

CEO: Dar-Jen Hsieh
Sector: Healthcare
Industry: Medical - Specialties
Exchange: TWO
Employees: 42
Website: www.acrobiomedical.com

Peers

Peers Tab

3176.TWO

Medigen Biotechnology Corp.

UnicoCell Biomed Co., Ltd.

Cap

NT$5.0B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6748.TWO

What does ACRO Biomedical Co., Ltd. do?: ACRO Biomedical Co., Ltd. (6748.TWO) operates in the Medical - Specialties industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6748.TWO's market cap?: ACRO Biomedical Co., Ltd. (6748.TWO) has a market capitalization of approximately $13.00 billion, as of August 27, 2026, based on the most recent share price and shares outstanding.
Does 6748.TWO pay a dividend?: No — ACRO Biomedical Co., Ltd. (6748.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6748.TWO profitable?: ACRO Biomedical Co., Ltd. (6748.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.